ABOUT Access antibodies
Access Antibodies focuses on developing innovating technologies that enable the intracellular access of antibody-based pharmaceuticals while maintaining target cell specificity. We leverage our technology platform to develop biopharmaceuticals that deliver cytotoxic payloads more efficiently into target tumor cells or to target 'undruggable' structures. In addition, we develop radiopharmaceuticals to provide improved tumor detection, increased radiation DNA damage, and to aide antibody-drug development.
Access Antibodies is a team effort including local and international students, postdocs, professional researchers, and physicians supervised by Dr. Jeff Leyton.
Current applications are against breast cancer and muscle invasive bladder cancer and always eager to partner with experts in additional diseases.
We engage with the local community to help improve the development of our biopharmaceuticals and, in turn, give back to patients.